drugset / Trial / NCT00483301
A Phase II Trial OF Carboplatin, ABI-007 (Abraxane) And Sorafenib (BAY 43-9006) in Metastatic Melanoma
Phase 2
Completed
34 enrolled
Mt. Sinai Medical Center, Miami
Bayer · collabCelgene Corporation · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to compare the effects, good and/or bad, of Carboplatin and ABI-007 (Abraxane) in combination with Sorafenib (BAY 43-9006) on Melanoma.
Timeline
- Start
- 2007-05
- Primary completion
- 2009-08
- Completion
- 2009-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ABI-007 | Unknown | — | — |
| Subject | Sorafenib | Small molecule | — | — |